Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents

Haijun Chen, Zhengduo Yang, Chunyong Ding, Lili Chu, Yusong Zhang, Kristin Terry, Huiling Liu, Qiang Shen, Jia Zhou

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide have hindered its further clinical development for cancer therapy. To discover new molecules with enhanced druglike properties, a series of novel O-alkylamino-tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.

Original languageEnglish (US)
Pages (from-to)180-185
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume4
Issue number2
DOIs
StatePublished - Feb 14 2013

Fingerprint

Niclosamide
Antineoplastic Agents
Derivatives
Neoplasms
Heterografts
Solubility
Transcriptional Activation
Biological Availability
Tumors
Chemical activation
Molecules
Therapeutics
Growth

Keywords

  • niclosamide derivatives
  • orally bioavailable
  • STAT3
  • water solubility

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. / Chen, Haijun; Yang, Zhengduo; Ding, Chunyong; Chu, Lili; Zhang, Yusong; Terry, Kristin; Liu, Huiling; Shen, Qiang; Zhou, Jia.

In: ACS Medicinal Chemistry Letters, Vol. 4, No. 2, 14.02.2013, p. 180-185.

Research output: Contribution to journalArticle

Chen, Haijun ; Yang, Zhengduo ; Ding, Chunyong ; Chu, Lili ; Zhang, Yusong ; Terry, Kristin ; Liu, Huiling ; Shen, Qiang ; Zhou, Jia. / Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. In: ACS Medicinal Chemistry Letters. 2013 ; Vol. 4, No. 2. pp. 180-185.
@article{f87e2e470b3748489c76094db56f4536,
title = "Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents",
abstract = "Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide have hindered its further clinical development for cancer therapy. To discover new molecules with enhanced druglike properties, a series of novel O-alkylamino-tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.",
keywords = "niclosamide derivatives, orally bioavailable, STAT3, water solubility",
author = "Haijun Chen and Zhengduo Yang and Chunyong Ding and Lili Chu and Yusong Zhang and Kristin Terry and Huiling Liu and Qiang Shen and Jia Zhou",
year = "2013",
month = "2",
day = "14",
doi = "10.1021/ml3003082",
language = "English (US)",
volume = "4",
pages = "180--185",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents

AU - Chen, Haijun

AU - Yang, Zhengduo

AU - Ding, Chunyong

AU - Chu, Lili

AU - Zhang, Yusong

AU - Terry, Kristin

AU - Liu, Huiling

AU - Shen, Qiang

AU - Zhou, Jia

PY - 2013/2/14

Y1 - 2013/2/14

N2 - Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide have hindered its further clinical development for cancer therapy. To discover new molecules with enhanced druglike properties, a series of novel O-alkylamino-tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.

AB - Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide have hindered its further clinical development for cancer therapy. To discover new molecules with enhanced druglike properties, a series of novel O-alkylamino-tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.

KW - niclosamide derivatives

KW - orally bioavailable

KW - STAT3

KW - water solubility

UR - http://www.scopus.com/inward/record.url?scp=84873692983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873692983&partnerID=8YFLogxK

U2 - 10.1021/ml3003082

DO - 10.1021/ml3003082

M3 - Article

VL - 4

SP - 180

EP - 185

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 2

ER -